This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Dr Rashmi Shah

Dr Rashmi Shah

Name:

Dr Rashmi Shah HonFBPhS

Organisation:

Pharmaceutical Consultant

Year elected:

2011

Primary professional setting:

Consultancy

Dr Shah specialised in cardiology and later, was the first to characterise the clinical significance of CYP2D6. Rashmi was Senior Clinical Assessor at the UK regulatory authority from 1987 to 2004 across almost all divisions and frequently nominated as Examiner for the Medicines Commission. He represented the UK at the EU Committee for Orphan Medicinal Products, various CHMP Working Parties, CIOMS Working Group on Pharmacogenetics and OECD Steering Group on Pharmacogenetics as well as the EU/EMA at the ICH E14 Topic on drug-induced QT interval. He co-authored a number of CHMP guidelines. He served on the Examining Board of the Faculty of Pharmaceutical Medicine and the Board of Studies for Pharmaceutical Medicine at the University of Surrey. His special interests include pharmacogenetics, phenoconversion, tyrosine kinase inhibitors, drug-induced QT prolongation and hepatotoxicity and drug interactions and has published over 90 papers and 20 chapters. Rashmi now provides consultancy service to the industry and has acted as Expert Witness in many product liability litigations.